Meticulous Research®—a leading market research company,
published a research report titled, ‘Microbubbles/Ultrasound Contrast Agents
Market by Application (Diagnostic Imaging [Cardiovascular, Renal, Abdominal,
Breast] Therapeutics) Type (Lipid, Protein, Polymer) End User (Hospitals &
Clinics, Diagnostics Laboratories) - Global Forecast to 2030.’
Download Free Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=3732?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=19-01-2024
According to this latest publication from Meticulous
Research®, the microbubbles/ultrasound contrast agents market is projected to
reach $1.95 billion by 2030, at a CAGR of 15.2% from 2023 to 2030. The aging
population, coupled with the rising prevalence of chronic diseases,
technological advancements in ultrasound imaging technologies, high demand for
image & diagnostics-guided procedures, and favourable reimbursement
policies for contrast-enhanced procedures, are driving the growth of this
market. In addition, increasing microbubbles/ultrasound contrast agents-related
research activities will likely offer growth opportunities for the market.
However, the complexity involved in contrast-enhanced ultrasound (CEUS) is
expected to restrain the market's growth to some extent.
The key players profiled in the microbubbles/ultrasound
contrast agents market report are Lantheus Holdings, Inc. (U.S.), GE HealthCare
Technologies Inc. (U.S.), Bracco S.p.A. (Italy), Bristol-Myers Squibb Company
(U.S.), Daiichi Sankyo Company, Limited (Japan), nanoPET Pharma GmbH (Germany),
Leriva (Greece), Siemens Healthineers AG (Germany), Bayer AG (Germany), and
Fujifilm Holdings Corporation (Japan).
TOP 10 COMPANIES IN MICROBUBBLES/ULTRASOUND CONTRAST
AGENTS MARKET >>> https://meticulousblog.org/top-10-companies-in-microbubbles-ultrasound-contrast-agents-market/?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=19-01-2024
The microbubbles/ultrasound contrast agents market is
segmented by type [lipid microbubbles, protein microbubbles, polymer
microbubbles], application [diagnostics imaging {cardiovascular imaging, renal
imaging, abdominal imaging, breast imaging, other diagnostics imaging
applications}, therapeutic applications], end user (hospitals & clinics,
diagnostics laboratories, other end users], and geography (North America,
Europe, Asia-Pacific, Latin America, and Middle East & Africa).
Based on type, in 2023, the lipid microbubbles segment is
expected to account for the largest share of the microbubbles/ultrasound
contrast agents market. Lipid-based microbubbles represent a new class of
agents with diagnostic and therapeutic applications. Stabilizing lipid-based
microbubbles creates low-density particles with unusual properties for
diagnostic imaging and drug delivery. Due to their advantages, research studies
are also carried out to widen their therapeutic applications, such as tumor-targeted
therapy, brain-targeted therapy, and immunotherapy. This further contributes to
the segment's largest share.
Based on application, the microbubbles/ultrasound contrast
agents market is segmented into diagnostics imaging and therapeutics. The
diagnostics imaging is further segmented into cardiovascular imaging, renal
imaging, abdominal imaging, and breast imaging. The diagnostics segment is
expected to account for the largest share of the microbubbles/ultrasound
contrast agents market in 2023. The large market share of this segment is
attributed to the increase in demand for radiation-free and non-invasive diagnostic
modalities for testing various disorders, including cardiovascular, breast, and
abdominal conditions.
Based on end user, in 2023, the hospitals & clinics
segment is expected to account for the largest share of the
microbubbles/ultrasound contrast agents market. The large market share of the
segment is attributed to the rise in the number of hospital admissions owing to
the significant rise in spending on health, the rising number of healthcare
facilities in emerging countries, and the well-established infrastructure of
hospitals and clinics.
Based on geography, in 2023, North America is expected to
account for the largest share of the microbubbles/ultrasound contrast agents
market. The rising demand for imaging and diagnostics-guided procedures, the
presence of several key market players, and advanced healthcare systems in
North America support the large share of this market.
Request Free Research Report Sample @ https://www.meticulousresearch.com/request-sample-report/cp_id=3732?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=19-01-2024
